EyeGate, Valeant Pharmaceuticals deal

EyeGate granted Valeant exclusive rights to develop and commercialize EGP-437 in combination with EyeGate II Drug Delivery System for anterior uveitis. EyeGate will receive $1 million upfront, and is eligible to receive up to $32.5 million in developmental and commercial milestones, plus high, single-digit royalties. EyeGate will be responsible for all development and regulatory costs in the U.S. Valeant will be responsible for all development and regulatory costs outside of the U.S. and will have exclusive rights to manufacture the product in the U.S. for the indication. ...